Achyut Healthcare Ltd. Approves Preferential Allotment of Equity Shares
Achyut Healthcare Ltd. announced on March 23, 2026, that its Board of Directors approved the allotment of 58,00,000 equity shares on a preferential basis to Promoter and Non-Promoter group shareholders. The shares are being issued at a premium of Rs.5 per equity share, with a face value of Re.1 per share.The company received a total consideration of ₹3,48,00,000 for the allotment of the 58,00,000 equity shares. The newly allotted shares will rank equally with existing shares regarding dividend payments and voting rights.
The issued, subscribed, and paid-up capital of the company following the allotment is detailed below:
| Particulars | Before Allotment | Value (Face value of ₹ 1/- each) | After Allotment | Value (Face value of ₹ 1/- each) |
|---|---|---|---|---|
| Issued Capital | 23,55,57,000 | 23,55,57,000 | 24,13,57,000 | 24,13,57,000 |
| Subscribed and Paid-up Capital | 23,55,57,000 | 23,55,57,000 | 24,13,57,000 | 24,13,57,000 |
The Board meeting commenced at 5:00 P.M. (IST) and concluded at 5:45 P.M. (IST).
Details of Allottees and Shareholding
The following table outlines the details of the allottees, their pre and post-preferential shareholding, and the number of equity shares allotted:
| Sr. No. | Allottee Name | Pre-Preferential Shareholding | Post-Issue Holding | No. of Shares Allotted |
|---|---|---|---|---|
| 1 | Akshit Mahendra Raycha | 2,07,90, 000 | 2,15,90, 000 | 8,00,000 |
| 2 | Mahendra C. Raycha HUF | 1,83,82, 770 | 1,91,82, 770 | 8,00,000 |
| 3 | Ray Remedies Private Limited | 77,17, 500 | 79,17, 500 | 2,00,000 |
| 4 | Zenith Lifecare Private Limited | - | 2,00,000 | 2,00,000 |
| 5 | Dhavalkumar Harshkantbhai | - | 10,00, 000 | 10,00,000 |
| 6 | Mayankbhai Harshkantbhai Ruparelia | - | 10,00, 000 | 10,00,000 |
| 7 | Strikar Lifescience LLP | - | 18,00, 000 | 18,00,000 |
| TOTAL | 58,00,000 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.